Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.25 CAD 0.45% Market Closed
Market Cap: 132.7m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Biosyent Inc
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biosyent Inc
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Biosyent Inc
XTSX:RX
Cash & Cash Equivalents
CA$9.3m
CAGR 3-Years
4%
CAGR 5-Years
-3%
CAGR 10-Years
7%
Bausch Health Companies Inc
TSX:BHC
Cash & Cash Equivalents
$719m
CAGR 3-Years
1%
CAGR 5-Years
-3%
CAGR 10-Years
-1%
Sundial Growers Inc
NASDAQ:SNDL
Cash & Cash Equivalents
CA$195m
CAGR 3-Years
48%
CAGR 5-Years
69%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Cash & Cash Equivalents
$848.2m
CAGR 3-Years
-2%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Cash & Cash Equivalents
$295.3m
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Cash & Cash Equivalents
$118.1m
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biosyent Inc
Glance View

Market Cap
130.3m CAD
Industry
Pharmaceuticals

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

RX Intrinsic Value
9.51 CAD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Biosyent Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
9.3m CAD

Based on the financial report for Jun 30, 2024, Biosyent Inc's Cash & Cash Equivalents amounts to 9.3m CAD.

What is Biosyent Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
7%

Over the last year, the Cash & Cash Equivalents growth was 63%. The average annual Cash & Cash Equivalents growth rates for Biosyent Inc have been 4% over the past three years , -3% over the past five years , and 7% over the past ten years .

Back to Top